Evidence map›Paper›PMID 29877511›Full record

ArticleOncotarget2018

Correction: Neuroprotective effects of bajijiasu against cognitive impairment induced by amyloid-β in APP/PS1 mice.

Haobin Cai, Yijie Wang, Jiayang He, Tiantian Cai, Jun Wu, Jiansong Fang, Rong Zhang, Zhouke Guo, Li Guan, Qinkai Zhan and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Neuroprotective Effects of OMO within the Hippocampus and Cortex in a D-Galactose and AEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Haobin CaiDepartment of Neurology & Psychology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
Yijie WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jiayang HeInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Tiantian CaiInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jun WuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Jiansong FangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Rong ZhangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Zhouke GuoDepartment of Neurology & Psychology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
Li GuanInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Qinkai ZhanInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Li LinGuangzhou University of Chinese Medicine, Guangzhou 510405, China.
Yao XiaoGuangzhou Medical University, Guangzhou 510182, China.
Huafeng PanInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Qi WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.21515.].

Identifiers

PMID29877511
PMCPMC5986648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.